Publications by authors named "G Maltezakis"
Introduction: Hemoptysis constitutes a common and urgent medical problem. Swift and effective management is of crucial importance, especially in severe, life-threatening cases. In cases of idiopathic hemoptysis, in which no underlying pulmonary pathology can be identified, treatment is challenging.
View Article and Find Full Text PDFWe describe a case of Streptomyces lanatus pneumonia in an immunocompetent 52-year-old woman. Bronchoalveolar lavage culture grew Streptomyces, which was identified by 16S rRNA sequencing. The infection resolved completely after successful treatment with doxycycline for 6 months.
View Article and Find Full Text PDFIdiopathic pulmonary fibrosis (IPF) is a deadly disease, largely unresponsive to treatment with corticosteroids and immunosuppressives. The aim of this randomized, prospective, open-label study was to characterize the molecular effects of IFN-gamma-1b and colchicine, on biomarkers expression associated with fibrosis (TGF-beta, CTGF) and immunomodulatory/antimicrobial activity (IFN-gamma), in the lungs of patients with IPF. Fourteen (14) patients with an established diagnosis of IPF received either 200 microg of IFN-gamma-1b subcutaneously three times per week, or 1mg of oral colchicine per day, for 24 months.
View Article and Find Full Text PDFBackground: The clinical presentation of hemoptysis often raises a number of diagnostic possibilities.
Objectives: This study was designed to evaluate the relative frequency of different causes of hemoptysis and the value of chest radiography, computed tomography (CT) scanning and fiber-optic bronchoscopy in the evaluation of a Greek cohort population.
Methods: We prospectively followed a total of 184 consecutive patients (137 males/47 females, 145 smokers/39 nonsmokers) admitted with hemoptysis between January 2001 and December 2003 to the University Hospital of Heraklion.
Article Synopsis
- - The study aimed to assess how effective and toxic the drug combination of irinotecan and gemcitabine is in patients with small-cell lung cancer who have previously undergone treatment.
- - Thirty-one patients were treated with specific doses of gemcitabine and irinotecan every 21 days, leading to a 10% overall response rate and 22% disease stabilization, with a median survival time of 6 months.
- - While the treatment showed limited effectiveness, it did not result in any toxic deaths and is suggested for further research in small-cell lung cancer patients who have already received chemotherapy.